HR Execs on the Move


 
At Behavioral Health Professionals, Inc. we take pride in offering expert behavioral health management services. It’s all we do.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.bhpi.org
  • 1333, Brewery Park Blvd
    Detroit, MI USA 48207
  • Phone: 313.656.2587

Executives

Name Title Contact Details

Similar Companies

Balance Autism

Balance Autism is a leading autism service organization in Iowa.

Red Light Holland

Red Light Holland`s goal is to, over time, help make the relatively unknown `magic truffle` a familiar name across the world. We are currently setting up to grow, distribute and market a premium brand of magic truffles to the legal, recreational market within the Netherlands, and we can`t wait to shift the existing paradigm to direct further attention to the legal and responsible use of magic truffles.

Immtech Pharmaceuticals

Immtech Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Freedom

New Freedoms 90-day reentry program inspires personal growth and accountability while treating substance abuse and other behavioral health needs.

Heron Therapeutics

Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action. The Company's lead product, SUSTOL™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration during the fourth quarter of 2014. Heron Therapeutics' core Biochronomer technology, on which SUSTOL and its other products are based, consists of bioerodible polymers designed to release drugs over a defined period of time. The Company has completed over 100 in vivo and in vitro studies demonstrating that its Biochronomer technology is potentially applicable to a range of therapeutic areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. Heron Therapeutics has also completed comprehensive animal and human toxicology studies that have established that its Biochronomer polymers are generally well tolerated. Furthermore, the Company's Biochronomer technology can be designed to deliver drugs over periods varying from days to several months. In addition to its lead drug candidate SUSTOL, Heron Therapeutics has a pipeline of other product candidates that use the Biochronomer technology.